Peter O’Brien Harris was a Texaco (Trinidad) worker who, as an amateur archaeologist half a century ago, excavated and described one of the most important Amerindian sites ever discovered—at Banwari
Novocure to Report First Quarter 2021 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure s management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2021, at 8 a.m. EDT on Thursday, April 29, 2021. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 2286525.
The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public inform
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Quarterly net income of $4.9 million with $0.05 in earnings per share
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the company s clinical and product development programs. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.
Fourth quarter 2020 highlights include:
Three Months Ended
(2)
5
(1) Adjusted EBITDA is a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation.